2024 Breakthroughs and Setbacks in Lysosomal Disorder Gene Therapies
Major developments in lysosomal disorder treatments marked 2024, with both advances and challenges in gene therapy approaches. Notable events included Roche's discontinuation of its Pompe disease program, promising progress in Fabry disease treatment by Sangamo, and mixed results in other rare disease therapies.
© Copyright 2025. All Rights Reserved by MedPath